Evidence map›Paper›PMID 37853362›Full record

ArticleBMC cancer2023

Validation of hypermethylated DNA regions found in colorectal cancers as potential aging-independent biomarkers of precancerous colorectal lesions.

Sija Sajibu, Emanuel Sonder, Amit Tiwari, Stephany Orjuela, Hannah R Parker, Olivier The Frans, Christoph Gubler, Giancarlo Marra, Mark D Robinson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sija SajibuInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Emanuel SonderDepartment of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, Zurich, 8057, Switzerland.
Amit TiwariInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Stephany OrjuelaInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Hannah R ParkerInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Olivier The FransDivision of Gastroenterology, Triemli Hospital, Zurich, Switzerland.
Christoph GublerDivision of Gastroenterology, Triemli Hospital, Zurich, Switzerland.
Giancarlo MarraInstitute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Mark D RobinsonDepartment of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, Zurich, 8057, Switzerland. mark.robinson@mls.uzh.ch.
University of Zurich · CHTriemli Hospital · CHSIB Swiss Institute of Bioinformatics · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_179477
6 · The paper itself

Abstract

backgroundWe previously identified 16,772 colorectal cancer-associated hypermethylated DNA regions that were also detectable in precancerous colorectal lesions (preCRCs) and unrelated to normal mucosal aging. We have now conducted a study to validate 990 of these differentially methylated DNA regions (DMRs) in a new series of preCRCs.

methodsWe used targeted bisulfite sequencing to validate these 990 potential biomarkers in 59 preCRC tissue samples (41 conventional adenomas, 18 sessile serrated lesions), each with a patient-matched normal mucosal sample. Based on differential DNA methylation tests, a panel of candidate DMRs was chosen on a subset of our cohort and then validated on the remaining part of our cohort and two publicly available datasets with respect to their stratifying potential between preCRCs and normal mucosa.

resultsStrong statistical significance for the difference in methylation levels was observed across the full set of 990 investigated DMRs. From these, a selected candidate panel of 30 DMRs correctly identified 58/59 tumors (area under the receiver operating curve: 0.998).

conclusionsThese validated DNA hypermethylation markers can be exploited to develop more accurate noninvasive colorectal tumor screening assays.

Indexed as

Colorectal NeoplasmsPrecancerous ConditionsAgingBiomarkers, TumorDNADNA MethylationHumansBiomarkers, TumorDNABiomarkers.Colorectal adenomaColorectal cancerDNA methylationSessile serrated lesion

Identifiers

PMID37853362
PMCPMC10585861
OpenAlexW4387733309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.